Key Factors
- CVS reported file 2025 income, exceeded EPS expectations, however maintained cautious future steering.
- CEO emphasised multi-year restoration and progress in remodeling healthcare expertise for People.
- BofA stays bullish; anticipates margin enchancment and raised adjusted EPS estimate for 2026.
CVS Well being’s newest fourth quarter and full 12 months 2025 earnings report, introduced on Feb 11, gave traders some respite as they struggled with the federal government’s cost indicators and rising medical prices, preserving them significantly on edge.
In its This fall, the medical insurance supplier reported $105.7 billion in income, up 8.2% 12 months over 12 months, and GAAP diluted EPS of $2.30 and adjusted EPS of $1.09, exceeding expectations.
For the complete 12 months, CVS reported a file $402.1 billion income with a GAAP diluted EPS of $2.30 and adjusted EPS of $6.75. The insurance coverage supplier additionally generated $10.6 billion in money stream from operations.
Whereas not elevating its 2026 outlook, CVS reiterated its adjusted EPS steering vary of $7 and $7.20. By way of steering, it trimmed its anticipated money stream to $9 billion, pushed by a shift in sure 2026 funds into late 2025.
The earnings name was extra centered on CVS’s multi-year restoration plan amid rising scrutiny of Medicare Benefit (MA) and pharmacy profit managers (PBM).
“Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices to improving navigation of health care, to being the front door of care across our country, we are well-positioned to achieve our ambition to be the most trusted health care company in America.” David Joyner, CVS Well being President and CEO.
CVS inventory is down 3% 12 months thus far.
Shutterstock
BofA echoes CVS’s development technique
CEO David Joyner framed 2025 as a 12 months of “progress for CVS Health” on the earnings name. The 12 months marked organizational repairs aimed toward driving the corporate to improved monetary efficiency.
In a be aware shared by Financial institution of America, the financial institution argues that CVS has “multiple levers” to maintain earnings rising in 2026 and likewise offset the 2027 MA preliminary charge discover.
Extra Well being Care:
However earlier than we head into the small print, let’s perceive what Medicare Benefit is and the way it impacts CVS.
Medicare Benefit is the insurance coverage plan that CVS sells by means of Aetna and is essentially funded by authorities funds set yearly by the Facilities for Medicare & Medicaid Providers (CMS).
If these funds, nonetheless, don’t hold tempo with inflation or rising medical prices, it instantly impacts the premiums shoppers (the vast majority of whom are seniors) pay.
In the meantime, the corporate is compelled to both tighten networks, reduce advantages, or improve premiums, thereby impacting the provider’s total development.
CVS’s earnings name was pushed by the 2027 advance charge discover from CMS, which David Joyner, CEO of CVS, famous as not reflective of present tendencies.
The proposed charge merely doesn’t match the extent of medical price pattern within the trade. We’re advocating for extra acceptable funding to make sure enough entry in addition to the soundness and sustainability of a program relied on by greater than half of the seniors on this nation.”
David Joyner
CEO, CVS Well being
Nonetheless, CVS stays centered on bettering margins within the Medicare enterprise, regardless of the “disappointing” charge discover.
BofA doesn’t see MA as a main place of danger for the pharmacy large, because it sees repricing in group Medicare Benefit and particular person MA pricing as a “low-hanging fruit” for margin enchancment.
And as talks are underway and the ultimate charge discover will solely are available in April, BofA thinks it could possibly be a “catalyst to shares” as it’d embrace higher charges.
CVS inventory was up 1.7% on Wednesday, including to its 2% acquire this previous week. In the meantime, it has seen a 39% inventory acquire over the 12 months however stays down 3% year-to-date.
Bullish retail pharmacy sector
CVS highlighted sturdy enterprise in retail pharmacy, with phase income of $37.7 billion in This fall 2025, up from $33.5 billion in This fall 2024, a 12.4% year-over-year improve.
The adjusted working earnings was additionally up 8.7% at $1.91 billion, and administration attributed the good points to CVS’s Ceremony Assist prescription file acquisitions, which elevated its pharmacy drug combine and prescription quantity.
Thus, highlighting the accretion gained from Ceremony Assist retailer acquisitions by the pharmaceutical retailer.
Veteran dealer Stephen Guilfoyle famous in TheStreetPro that, with complete belongings amounting to “$253.538 billion, which includes $110.986 billion in assets labeled as either goodwill or other tangibles,” this represents virtually 44% of complete belongings, and he doesn’t “love” it.
Guilfoyle added that whereas “this is not a strong balance sheet, but it’s not a PepsiCo level train wreck either.”
In pharmacy and well being providers, CVS posted $51.24 billion This fall income, up 9.0% yoy, and an adjusted working earnings of $1.92 billion, up 9.2%. However CVS acknowledged that the continuing consumer worth enhancements did offset a number of the advantages it gained from inflation in brand-name medication and pharmacy drug combine.
By way of insurance coverage, CVS Aetna reported $36.39 billion in This fall income, up from the $34.96 billion reported in This fall 2024. However it nonetheless reported an adjusted working loss of $676 million, vs. the $439 million loss a 12 months in the past. The loss was largely attributed to Medicare Half D seasonality adjustments associated to the Inflation Discount Act and quarter-specific gadgets.
CVS ended 2025 with 26.6 million members, down 112,000 from Sept 2025, partially offset by a rise in Industrial ASC membership. Its Medical membership fell by 504,000 12 months over 12 months, reflecting declines in particular person alternate and authorities product traces.
BofA’s future predictions for CVS
- Reiterated its Purchase score and $95 worth goal.
- Expects margin enchancment in Oak Avenue with extra clinic closures, fewer new openings, and rising affected person panels to interrupt even.
- Elevated 2026 adjusted EPS estimate from $7.13 to $7.17 because of enhancements in well being care advantages (HCB) and pharmacy & client wellness (PCW).
- Lowered 2027 adjusted EPS from $8.23 to $8.21.
- For CVS’s Well being Providers, BofA elevated EBIT from $7.25 billion to $2.28 billion
- For OCW, it elevated its EBIT estimate from $6.09 billion to $6.13 billion.
- For HCB, it elevated its EBIT estimate from $3.73 billion to $3.74 billion, reflecting “execution on margin improvements in Aetna.”
We consider CVS is properly positioned for a “controlled acceleration” in 2025 pushed by the recapture of Medicare Benefit (MA) Star score bonus funds and full seize of upper MA utilization in pricing.
In regards to the authors
Shares Author, The Avenue
Aparajita Chatterjee holds a Grasp’s in Enterprise and Financial Reporting from New York College. At TheStreet, she analyzes the intersection of tech, vitality, and synthetic intelligence, specializing in information heart infrastructure, vitality demand, rising tech tendencies, federal insurance policies driving market shifts, and employment/layoffs.
Dana Sullivan Kilroy has been a journalist for greater than 25 years. She covers retail, recollects and sophistication motion lawsuits, in addition to Las Vegas journey for TheStreet. Her work has appeared in The New York Occasions, Actual Easy, Self, Exterior, BabyCenter, On a regular basis Well being, and WebMD. Dana holds a Grasp’s in Journalism from the College of Nevada, Reno, and a Bachelor’s in English Literature from UCLA. She lives in Nevada.
